Schiff-base cross-linked pullulan-chondroitin sulfate hydrogel incorporating raloxifene-poly(2-methyl-2-oxazoline) micelles for localized therapy of postmenopausal osteoarthritis.
Postmenopausal osteoarthritis (OA) is a degenerative joint disorder characterized by cartilage erosion and subchondral bone loss, intensified by estrogen deficiency in menopausal women. Raloxifene (RLX), a selective estrogen receptor modulator, shows anti-inflammatory and chondroprotective potential but is associated w...